CRISPR Therapeutics (CRSP) on Saturday announced new results from a Phase 1 trial for CTX310, an in vivo gene editing therapy for patients with high levels of triglycerides and low-density lipoprotein (LDL) cholesterol, also known as “bad” cholesterol.

After a